RE:RE:RE:RE:Lean HEAVILY on Birch Hill and Toray as your "Fiduciarys"... Yeah, they will have to call this Anthony guy soon to help get some money in the door.
By the way, what do you guys think will happen after the financing, if there is one. Price will go up or down? Do they get options for a successful financing?
SouthernTierTom wrote: Approach the Board with contact through Anthony Biehl III our trusted and long-time Chairman.
A great guy with HUGE experience and more ethics than anyone could ever ask for - JMHO
Birch Hill owns about 36 MILLION shares and Toray about 45 MILLION....
* EACH has a longtime board member ytheir to serve ALL shareholders in a "fiduciary manner"
I know the term "friends" gets tossed around like an American football... BUT in this particular case........these Heavy-weight players are INDEED there to stand with ALL shareholders.
Know that Birch Hill actually has a key partner of the firm sitting on the BMO board of directors....
This is good stuff and shows just what a wonderful company Birch Hill is...lean on them..they are our "Friends" IMHO.
I would mostly read and understand this..IMHO, it is indeed important;
So let's get this straight.... now the FAILED phase 3 Euphrates trial formulates a 75% weighting in a FDA phase 3B confirmatory trial where 2 of every 3 patients in a critical care setting with a primary endpoint of 28 day mortality ACTUALLY get the FAILED device from the phase 3. REALLY? What is next, do we spin $5M USD from a major pharma like say, Baxter into a liability and print 100M shares with the precision of an insider based "personalized investment program" When does 60 Minutes do a full hour on this one? Nevermind 15 minutes on experimental Exthera, this has waaay more cache baby!... it has cache up the ying-yang, where the ying-yang-ed is the retail invester.
There is a reason you were told not to put money in your mouth as a kid...it is very dirty...especially the BIG bills..cuz people like to keep them on the outside so to look prosperous.